PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in three upcoming investor conferences in November:
- Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference: Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat on Monday, November 6, 2023 at 9:50 a.m. ET in New York, NY. Members of management will also be available for one-on-one meetings.
- Stifel 2023 Healthcare Conference: Gwendolyn Binder, Ph.D., President of Science and Technology, will participate in a fireside chat on Tuesday, November 14, 2023 at 4:45 p.m. ET in New York, NY. Members of management will also be available for one-on-one meetings.
- 6th Annual Evercore ISI HealthCONx Conference: Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat on Wednesday, November 29, 2023 at 8:20 a.m. ET in Miami, FL. Members of management will also be available for one-on-one meetings.
A live webcast of the presentations will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus, myositis, and systemic sclerosis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Stern Investor Relations, Inc.
william.gramig@sternir.com
